Allopathic Treatment for diabetic patients

Treatment for type 2 diabetic patients

When your type 2 diabetic patient is uncontrolled with metformin  monotherapy, Switch to 

Sitagliptin+Metformin Combination

Combination is a novel drug that provides both STRENGTH & SAFETY.This combination is that the first ever FDA approved DPP-4 ( dipeptidyl peptidase 4) in the world.

Sitagliptin assists metformin to exert its additional benefit on GLP-1 & GIP enhancement. (Source no-1)

 

For Patients with HbA1c>8%, initial therapy with sitagliptin-metformin provides effective reduction in HbA1c,FPG and  PPG.  (Source no-2)

For patients withHbA1c>7.5, initial therapy with sitagliptin-metformin provides very low rate of hypoglycemia compared to placebo or monotherapies. (Source no-3)

For patients with HbA1c>8%,initial combination therapy with sitagliptin-metformin provides larger improvements in beta-cell function than with placebo or monotherapies. (Source no-4)

We can conclude that sitagliptin-metformin delivers

Action against 3 key defects of type 2 diabetes. (Source no-1)

Acts on

# Reduced insulin secretion

# Increase insulin resistance

# Hepatic glucose overproduction.

Efficacy (Source no-1)

# Effective reduction in HbA1c

# Effective reduction in FPG & PPG

Safety

# Very low rate of hypoglycemia with no severity 

# Increase beta-cell function

# No risk of weight gain.

Reference or source

1. JANUMET LPC-MK0431A-09201O

2.CURRENT MEDICAL RESEARCH AND OPTION

3. DIABETES CARE

4. DIABETES, OBESITY AND MRTABOLISM

5. CLINICAL MEDICINE INSIGHTS